We are live on ! Find out more
PTJ

Paul Tudor Jones Tudor Investment Corp

AUM $71.9B
1-Year Est. Return 42.37%
 

Paul Tudor Jones is the founder of Tudor Investment Corporation and a pioneering macro trader. He rose to prominence after navigating the 1987 market crash successfully and has since built a multi-strategy firm spanning global markets. Jones is widely associated with discretionary macro trading, risk management discipline, and high-profile philanthropic efforts in education and the environment.

This Fund
S&P 500
This Quarter Est. Return
+4.65%
1 Year Est. Return
+42.37%
3 Year Est. Return
+108.76%
5 Year Est. Return
+114.43%
10 Year Est. Return
+640.77%
AUM
$2.61B
AUM Growth
+$250M
Cap. Flow
+$161M
Cap. Flow %
6.15%
Top 10 Hldgs %
45.81%
Holding
1,510
New
336
Increased
390
Reduced
392
Closed
367

Sector Composition

Rank Sector Weight
1 Technology 13.51%
2 Healthcare 11.03%
3 Industrials 10.52%
4 Consumer Discretionary 7.22%
5 Financials 4.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SEMG
1401
DELISTED
SEMGROUP CORPORATION
SEMG
-4,155
Closed -$273K
CBM
1402
DELISTED
Cambrex Corporation
CBM
-18,500
Closed -$349K
ORIT
1403
DELISTED
Oritani Financial Corp. New
ORIT
-35,123
Closed -$555K
AREX
1404
DELISTED
Approach Resources Inc.
AREX
-16,500
Closed -$345K
DFRG
1405
DELISTED
Del Frisco's Restaurant Group, Inc. Common Stock
DFRG
-16,649
Closed -$464K
CHSP
1406
DELISTED
Chesapeake Lodging Trust
CHSP
-8,891
Closed -$229K
CTRL
1407
DELISTED
Control4 Corporation
CTRL
-37,391
Closed -$793K
WP
1408
DELISTED
Worldpay, Inc.
WP
-7,100
Closed -$215K
PETX
1409
DELISTED
Aratana Therapeutics, Inc.
PETX
-10,000
Closed -$186K
HF
1410
DELISTED
HFF Inc.
HF
-8,544
Closed -$287K
BRS
1411
DELISTED
Bristow Group, Inc.
BRS
-4,600
Closed -$347K
HZNP
1412
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-16,733
Closed -$253K
ULTI
1413
DELISTED
Ultimate Software Group Inc
ULTI
-2,200
Closed -$301K
AKAO
1414
DELISTED
Achaogen Inc
AKAO
-20,000
Closed -$309K
TFCFA
1415
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
-7,133
Closed -$228K
ESL
1416
DELISTED
Esterline Technologies
ESL
-2,900
Closed -$309K
NTRI
1417
DELISTED
NutriSystem, Inc.
NTRI
-16,200
Closed -$244K
ELGX
1418
DELISTED
Endologix Inc
ELGX
-1,756
Closed -$226K
NFX
1419
DELISTED
Newfield Exploration
NFX
-8,483
Closed -$266K
OCLR
1420
DELISTED
Oclaro Inc.
OCLR
-11,596
Closed -$36K
SONC
1421
DELISTED
Sonic Corp
SONC
-9,718
Closed -$221K
AFSI
1422
DELISTED
AmTrust Financial Services, Inc.
AFSI
-13,390
Closed -$252K
EVHC
1423
DELISTED
Envision Healthcare Holdings Inc
EVHC
-18,544
Closed -$1.88M
PHH
1424
DELISTED
PHH Corporation
PHH
-10,342
Closed -$267K
ANDV
1425
DELISTED
Andeavor
ANDV
-5,292
Closed -$268K

Similar funds

Paul Tudor Jones's Q2 2014 Portfolio in Review

As of Q2 2014, Paul Tudor Jones held 1,510 positions worth $2.61B, up 11% from $2.36B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Paul Tudor Jones deployed $161M of net new capital in Q2 2014, opening 336 new positions and adding to 390 existing holdings. Its largest new stake was Apple: 5,248,200 shares worth $122M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 9.3% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Pfizer, an estimated $25.8M trimmed.

  • Paul Tudor Jones's largest Q2 2014 buy was Apple: 5,248,200 shares worth $122M.
  • Paul Tudor Jones added most to iShares MSCI Emerging Markets ETF in Q2 2014, an estimated $79.6M increase.
  • Paul Tudor Jones's biggest Q2 2014 reduction was Pfizer, cutting an estimated $25.8M.
  • Paul Tudor Jones fully exited iShares iBoxx $ High Yield Corporate Bond ETF in Q2 2014, selling an estimated $104M.
  • Paul Tudor Jones's ten largest holdings make up 46% of its $2.61B portfolio in Q2 2014.
  • Paul Tudor Jones opened 336 new positions and closed 367 in Q2 2014.
  • Paul Tudor Jones's portfolio value rose 11% quarter-over-quarter to $2.61B.

Based on Tudor Investment Corp's 13F filing for Q2 2014, filed 14 Aug 2014.